Structure-Based Druggability Assessment of the Mammalian Structural Proteome with Inclusion of Light Protein Flexibility

PLoS Computational Biology

Volumn 10, Issue 7, 2014, Pages

  Loving, Kathryn A ^a,c   Lin, Andy ^b   Cheng, Alan C ^b  

^a SCHRÖDINGER INC   (United States)

^b AMGEN INC   (United States)

^c Stem CentRx   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING SITES; CRYSTAL STRUCTURE; MAMMALS;

CRYSTAL STRUCTURE DATA; CRYSTALS STRUCTURES; ESTIMATION METHODS; IMPROVED STRUCTURES; INTERACTION INTERFACE; PROTEIN CRYSTAL; PROTEIN FLEXIBILITY; PROTEIN MODELS; PROTEIN-PROTEIN INTERACTIONS; STRUCTURE-BASED;

PROTEINS;

PROTEOME; STRUCTURAL PROTEIN; DRUG; NAPHTHALENE; NAPHTHALENE DERIVATIVE; PROTEIN; PROTEIN BINDING;

ANALYTIC METHOD; ARTICLE; BINDING SITE; CHEMICAL PARAMETERS; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG RESEARCH; MAMMAL; MOLECULAR MODEL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN FLEXIBILITY; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; STRUCTURE BASED DRUGGABILITY APPROACH; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; METABOLISM; PLIABILITY; PROCEDURES; PROTEIN CONFORMATION; PROTEOMICS; REPRODUCIBILITY; STATISTICAL MODEL;

ANIMALS; BINDING SITES; DRUG DESIGN; MAMMALS; MODELS, MOLECULAR; MODELS, STATISTICAL; NAPHTHALENES; PHARMACEUTICAL PREPARATIONS; PLIABILITY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEINS; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS;

EID: 84905454868     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003741     Document Type: Article

References (38)

1. Macarron R, (2006) Critical review of the role of HTS in drug discovery. Drug Discov Today 11: 277-279.
2. Hopkins AL, Groom CR, (2002) The druggable genome. Nature Rev Drug Discov 1: 727-730.
3. Cheng AC, (2008) Predicting selectivity and druggability in drug discovery. Annual Reports Comp Chem 4: 23-37.
4. Cheng AC, Coleman RG, Smyth KT, Cao Q, Soulard P, et al. (2007) Structure-based maximal affinity model predicts small molecule druggability. Nature Biotech 25: 71-75.
5. Lipinski CA, (2005) Filtering in drug discovery. Annual Reports Comp Chem 1: 155-168.
6. Fauman EB, Rai BK, Huang ES, (2011) Structure-based druggability assessment-identifying suitable targets for small molecule therapeutics. Curr Opin Chem Biol 15: 463-468.
7. Sheridan RP, Maiorov VN, Holloway MK, Cornell WD, Gao YD, (2010) Drug-like density: a method of quantifying the "bindability" of a protein target based on a very large set of pockets and drug-like ligands from the Protein Data Bank. J Chem Inf Model 50: 2029-2040.
8. Seco J, Luque FJ, Barril X, (2009) Binding site detection and druggability index from first principles. J Med Chem 52: 2363-2371.
9. Beuming T, Che Y, Abel R, Kim B, Shanmugasundaram V, et al. (2012) Thermodynamic analysis of water molecules at the surface of proteins and applications to binding site prediction and characterization. Proteins 80: 871-883.
10. Wells JA, McClendon CL, (2007) Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450: 1001-1009.
11. Eyrisch S, Helms V, (2007) Transient pockets on protein surfaces involved in protein-protein interaction. J Med Chem 50: 3457-3464.
12. Basse MJ, Betzi S, Bourgeas R, Bouzidi S, Chetrit B, et al. (2013) 2P2Idb: A Structural Database Dedicated to Orthosteric Modulation of Protein-Protein Interactions. Nucleic Acid Research 41: D824-827.
13. Halgren TA, (2009) Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model 49: 377-389.
14. Jordan JB, Poppe L, Xia X, Cheng AC, Sun Y, et al. (2012) Fragment based drug discovery: practical implementation based on 19F NMR spectroscopy. J Med Chem 55: 678-687.
15. Gustin DJ, Li Y, Brown ML, Min X, Schmitt MJ, et al. (2013) Structure guided design of a series of sphingosine kinase (SphK) inhibitors. Bioorg Med Chem Lett 23: 4608-4616.
16. Sherman W, Day T, Jacobson MP, Friesner RA, Farid R, (2006) Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 49: 534-553.
17. Huang N, Jacobson MP, (2010) Binding-site assessment by virtual fragment screening. PLoS One 5: e10109.
18. Kozakov D, Hall DR, Chuang GY, Cencic R, Brenke R, et al. (2011) Structural conservation of druggable hot spots in protein-protein interfaces. Proc Natl Acad Sci USA 108: 13528-13533.
19. Grove LE, Hall DR, Beglov D, Vajda S, Kozakov D, (2013) FTFlex: accounting for binding site flexibility to improve fragment-based identification of druggable hot spots. Bioinformatics 29: 1218-1219.
20. Bakan A, Nevins N, Lakdawala AS, Bahar I, (2012) Druggability assessment of allosteric proteins by dynamics simulations in the presence of probe molecules. J Chem Theory Comput 8: 2435-2447.
21. Brown SP, Hajduk PJ, (2006) Effects of conformational dynamics on predicted protein druggability. ChemMedChem 1: 70-72.
22. Kokh DB, Richter S, Henrich S, Czodrowski P, Rippmann F, et al. (2013) TRAPP: a tool for analysis of transient binding pockets in proteins. J Chem Inf Model 53: 1235-1252.
23. Schmidtke P, Bidon-Chanal A, Luque FJ, Barril X, (2011) MDpocket: open-source cavity detection and characterization on molecular dynamics trajectories. Bioinformatics 27: 3276-3285.
24. Ivetac A, McCammon JA, (2012) A molecular dynamics ensemble-based approach for the mapping of druggable binding sites. Methods Mol Biol. 819: 3-12.
25. Lexa KW, Carlson HA, (2011) Full protein flexibility is essential for proper hot-spot mapping. J Am Chem Soc 133: 200-202.
26. Shan Y, Kim ET, Eastwood MP, Dror RO, Seeliger MA, et al. (2011) How does a drug molecule find its target binding site? J Am Chem Soc 133: 9181-9183.
27. Ngan CH, Bohnuud T, Mottarella SE, Beglov D, Villar EA, et al. (2012) FTMAP: extended protein mapping with user-selected probe molecules. Nucleic Acids Res 40: W271-275.
28. He MM, Smith AS, Oslob JD, Flanagan WM, Braisted AC, et al. (2005) Small molecule inhibition of TNF-alpha. Science 310: 1022-1025.
29. Lee EF, Czabotar PE, Smith BJ, Deshayes K, Zobel K, et al. (2007) Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ 14: 1711-1713.
30. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Res 28: 235-242.
31. Faure G, Andreani J, Guerois R, (2012) InterEvol database: Exploring the structure and evolution of protein complex interfaces. Nucleic Acids Res 40: D847-56 (Used July 2012 release from http://biodev.cea.fr/interevol/, downloaded May 26, 2013.).
32. Coleman RG, Salzberg AC, Cheng AC, (2006) Structure-based identification of small molecule binding sites using a free energy model. J Chem Inf Model 46: 2631-2637.
33. Johnson DK, Karanicolas J, (2013) Druggable protein interaction sites are more predisposed to surface pocket formation than the rest of the protein surface. PLoS Comput Biol 9: e1002951.
34. Kufareva I, Ilatovskiy AV, Abagyan R, (2012) Pocketome: an encyclopedia of small-molecule binding sites in 4D. Nucleic Acids Res 40: D535-40.
35. Patel MN, Halling-Brown MD, Tym JE, Workman P, Al-Lazikani B, (2013) Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov 12: 35-50.
36. Martin AC (2005) Mapping PDB chains to UniProtKB entries. Bioinformatics 21: 4297-4301. Downloaded March 6, 2013 update.
37. Mudunuri U, Che A, Yi M, Stephens RM, (2009) bioDBnet: the biological database network. Bioinformatics 25: 555-556.
38. The PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC.